Cathepsin K inhibitors: a novel target for osteoporosis therapy
SA Stoch, JA Wagner - Clinical Pharmacology & Therapeutics, 2008 - Wiley Online Library
SA Stoch, JA Wagner
Clinical Pharmacology & Therapeutics, 2008•Wiley Online LibraryOsteoporosis is characterized by low bone mass with skeletal fragility and an increased risk
of fracture. This bone loss is brought about by an imbalance between bone resorption and
formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast
and is believed to be instrumental in bone matrix degradation necessary for bone resorption.
Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis
and other disorders characterized by increased bone resorption. Clinical Pharmacology & …
of fracture. This bone loss is brought about by an imbalance between bone resorption and
formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast
and is believed to be instrumental in bone matrix degradation necessary for bone resorption.
Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis
and other disorders characterized by increased bone resorption. Clinical Pharmacology & …
Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption.
Clinical Pharmacology & Therapeutics (2008) 83, 172–176; doi:10.1038/sj.clpt.6100450
Wiley Online Library